GCG and metabolic dysfunction-associated steatotic liver disease: Therefore, incretin agonists, either alone or in combination, seem an appealing and effective therapeutic opportunity for the disease, as they not only modify liver-related pathways but also act on other tissues affected by MASLD, which have a critical impact on MASLD-related morbidity and mortality.